Anusha Muralidhar, MS; Carolina Ferreria, PhD; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD, Immune contexture;Immune suppression;MDSC;Myeloid cells;Radiotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment. Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studies. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Fibroblast activation protein regulates human natural killer cell migration. ; Tim Sauer, MD; Cliona Rooney, PhD; Robin Parihar, MD, PhD, MDSC;NK/NKT cell;Pediatric tumors;Solid tumors;Tumor microenvironment, Engineering non-activated CAR T cells with enhanced potency against advanced cancers, Saba Ghassemi, PhD; Joseph S. Durgin, MD; Frederic D. Bushman, PhD; Saar I. Gill, MD, PhD; Roddy S. O'Connor, PhD; Michael C. Milone, Investigating the role of the endogenous CD28 co-stimulatory receptor in achieving optimal CAR-T cell therapeutic efficacy, Mackenzie M. Honikel; Kelvin P. Lee, MD; Scott H. Olejniczak, PhD, Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies, Sabina Kaczanowska, PhD; Sneha Ramakrishna, MD; Tara Murty, BS; Cristina F. Contreras; Ahmad Alimadadi, PhD; Norma Gutierrez; Aashna Jhaveri; Yang Liu; Jennifer Altreuter, MD; Franziska Michor; Caroline Duault, PharmD, PhD; Priyanka Balasubrahmanyam; Warren Reynolds; Reema Baskar, PhD; Mina Pichavant; Bita Sahaf, PhD; Sean C. Bendall, PhD; Holden T. Maecker, PhD; Melinda Merchant, MD, PhD; Crystal Mackall, MD; Catherine C. Hedrick, PhD; Rosandra N. Kaplan, MD, CAR T cells;Clinical study;Immune contexture;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;T cell, Expansion of therapeutic NK cell line under hypoxic and hyperbaric culture conditions enhances anti-tumor potency, James Lim, PhD; Ann Lu, PhD; Yunmin Li, PhD; Yelena Bronevetsky, PhD, Adoptive immunotherapy;CAR T cells;Immune suppression;Metabolism;NK/NKT cell;Tumor microenvironment, Developing a new targeted therapy for pediatric rhabdomyosarcoma: v3 and HER2 as promising targets for bispecific CAR T-cell therapy, Amanda M. Lulu, PhD; Joseph J. Caruso, BS; Dustin A. Cobb, PhD; Daniel W. Lee, III, MD, Bispecifics;CAR T cells;Pediatric tumors;Solid tumors;Tumor evasion, PDGFR-specific CAR T cell therapy of pediatric high-grade glioma. Bai, PhD; Anand V. Kornepati, PhD; Carlos O. Ontiveros, BS; Yilun Deng, PhD; Alvaro S. Padron; Eva M. Galvan; Myrna G. Garcia, BS; Tyler J. Curiel, MD, Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor microenvironment, Real-world treatment patterns among patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) in a community oncology setting, Eric Nadler, MD MPP; Christopher M. Black, PhD; Karthik Ramakrishnan; Wan-Yu Tseng; Chuck Wentworth; John Murphy; Nicole Fulcher; Liya Wang; Melannie Alexander; Gregory Patton, Chemotherapy;Radiotherapy;Solid tumors;Targeted therapy, Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo, Fredrik G. Oberg, PhD; Sujata Bhoi, PhD; Malene Jensen, PhD; Tom Morris, MD; Karin Tunblad, PhD; Hans Wallberg, PhD, Checkpoint blockade;Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs), Patterns and Outcomes of Palliative Radiation Therapy with Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Logan Roof, MD; Anirudh Yalamanchali, MD; David Buchberger, MD; Shauna Campbell, DO; Shlomo Koyfman, MD; Neil M. Woody, MD; Natalie Silver, MD, MS, FACS; Jessica L. Geiger, MD; Emrullah Yilmaz, MD, PhD, Checkpoint blockade;Costimulation;Radiotherapy, Efficacy of Pembrolizumab as cross-line treatment in advanced non-small cell lung cancer: a multi-center non-interventional study from China, Kexin Ruan; Jing Zheng; Jianying Zhou; Yuping Li; Xiaodong Lv; Xiaoyu Wu; Liren Ding; Jianya Zhou, MD, Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study, Characterization of HZ-G206: A potent and oral small molecule PD-L1 inhibitor, Yizhe Wu, PhD; Xingguo Liu, PhD; Xinxin Jin; Jinglai Huang; Xinglu Zhou, Gene therapy with p19Arf and interferon-beta sensitizes cells to PD-1 checkpoint blockade and enhances antitumor immune responses in resistant mouse models, Ana Domingues, BS; Nayara Tessarollo; Bryan Strauss, Checkpoint blockade;Gene expression;Solid tumors, Discovery of Potent Cbl-b inhibitors Demonstrating Enhanced Immune Cell Activity and Tumor Growth Inhibition in Murine Syngeneic Models, B cell;Checkpoint blockade;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell, Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3, Eleanor Clancy-Thompson, PhD; Trinity L. Perry; Stacy Pryts; Ashvin Jaiswal, PhD; Vaheh Oganesyan; Nydia van Dyk; Chunning Yang; Andrew Garcia; Wenhan Yu; James R. Moynihan, MS; Caroline Miller; Kathy A. Mulgrew; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD, Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Genetic polymorphism;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs), PD-L1/PD-L2 dual-specific cytotoxic antibodies augment survival and mediate tumor regression across immune 'hot' and 'cold' murine cancers, Coline A. Couillault, PhD; Anupallavi Srinivasamani, MS; Shweta M. Hedge; Qinying Liu; Guillaume Trusz; Ashvin Jaiswal, PhD; Dongxing Zha; Michael A. Curran, PhD, Antibody;Bispecifics;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Investigating the T cell-intrinsic regulatory role of VISTA in anti-tumor immunity, Cassandra K. Gilmour, BS; Yikun Wang; Sachin Patnaik, BA; Sarah Stone; Li Wang, PhD, Checkpoint blockade;Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Anti-CTLA-4 therapy depletes Tregs and expands ICOS+ T-cells in neuroblastoma tumors with induced DNA mismatch repair deficiency, Megan Hong, BMSc; Rene Figueredo, MSc; Saman Maleki, PhD, Checkpoint blockade;Costimulation;Neoantigens;Pediatric tumors;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), Synergistic approach to overcome the solid tumor microenvironment of mesothelioma with natural killer cell-focused immunotherapy, Philippa (Pippa) R. Kennedy, PhD; Quinlan M. Kile; Blake A. Jacobson, PhD; Brianna Ettestad; Sarah E. Miller; Jeffrey S. Miller, MD; Manish R. Patel, DO; Martin Felices, Antibody;Checkpoint blockade;Costimulation;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment. Melero, MD, PhD, Adoptive immunotherapy;CAR T cells;Cytokine;Metabolism;RNA;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells, Alessia Potenza, PhD; Chiara Bonini, MD; Chiara Balestrieri; Luca Albarello; Federica Pedica; Martina Spiga; Francesco Manfredi; Beatrice C. Cianciotti; Claudia De Lalla; Lorena Stasi; Elena Tassi; Silvia Bonfiglio; Giulia M. Scotti; Miriam Redegalli; Donatella Biancolini; Danilo Abbati; Fabio Simeoni; Dejan Lazarevic; Ugo Elmore; Guido Fiorentini; Giulia Di Lullo; Giulia Casorati; Paolo Dellabona; Claudio Doglioni; Giovanni Tonon; Riccardo Rosati; Luca Aldrighetti; Eliana Ruggiero, PhD, Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Mitochondrial apoptosis mediates CAR T cell cytotoxicity, Alexandra L. Pourzia, MD, PhD; Michael L. Olson, PhD; Stefanie R. Bailey, PhD; Aditi Aryal, BS; Jeremy Ryan, MS; Marcela V. Maus, MD, PhD; Anthony Letai, PhD MD, CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Tumor evasion, Developing placental CD34+-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with Avelumab for enhanced therapy against PD-L1+ solid tumors, Irene Raitman, PhD; Gavin Foley; Eric He; Hemlata Rana, MS; Niranjan Ghimire, PhD; Xuan Guo, PhD; Robert Hariri, MD PhD; Lin Kang, PhD, Antibody;Checkpoint blockade;Solid tumors;Tumor antigens. Christine A. Tran, MD; Gabrielle H. Schwartzman, MD; Walter C. Olson, Jr., PhD; Kelly T. Smith; Jennifer L. Bryant; Craig L. Slingluff, Jr., MD; A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors, Clinical trial;Targeted therapy;Tumor microenvironment. They will learn up-to-date progress, explore unresolved questions in the field and meet world-class experts. A Transgenic Line That Reports CSF1R Protein Expression Provides a Definitive Marker for the Mouse Mononuclear Phagocyte System. Abbott, DPhil; Okba Alassadi; Matthew Davies; Magdalena Von Essen; Vernica Freire-Benitez; Vicki Jefferson; Samit Kundu; Prathiba Kurupati; Ralf M. Leonhardt; Samuel Lukowski; Fabio Marino; Giulia Masi; Rayner ML. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Refer to microglia in basal conditions as homeostatic instead of resting microglia, considering the limitations discussed above (i.e., that these terms refer to microglia under physiological conditions and not to the function of microglia). Olcina, PhD; Mark D. Robinson, PhD; Carsten Krieg, PhD, Checkpoint blockade;Inflammation;Microbiome;Solid tumors, The Role of VSIG4 as an Immuno-Regulatory protein in cancer, William Huang, BS; Michele Doucet; Rupashree Sen; Andrew M. Pardoll, MD, PhD; Sudipto Ganguly, PhD, Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment, GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy, Haemi Kim; Kyoung-Jin Kim; Myeong Jin Yoon; Jenny Choih, PhD; Eun Ji Cho; Hak-Jun Jung, PhD; Kwanghyun Lee, PhD; Jayoung Kim; Chae Gyu Park; Sungho Han, PhD; Donggoo Bae; Heungrok Park, Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor microenvironment, NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity, McKenna Lamb; Yao Wei; Xiaoxin Ren; Rachel O'Connor; Austin Dulak, PhD; Matthew Rausch, PhD; Jamie Strand, PhD; Bijan Etemad-Gilbertson, PhD; Riale Gilligan; Scott Chappel, PhD; Tomonari Shigemura; David McDermott, MD; Gordon J. Freeman, PhD; XingXing Zang, PhD, Antibody;Checkpoint blockade;Coinhibition;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs), Galectin-9 drives TIM-3+ natural killer cell dysfunction in head and neck squamous cell carcinoma, Lazar Vujanovic, PhD; Housaiyin Li; Juncheng Wang; Aditi Kulkarni; Jennifer L. Anderson, M.D., Ph.D.; Lidia M. Arantes; Hridesh Banerjee, PhD; Lawrence P. Kane, PHD; Xin Zhang; Tullia Bruno, PhD; Riyue Bao, PhD; Robert L. Ferris, MD, PhD, Checkpoint blockade;Gene expression;Immune suppression;NK/NKT cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications, Xiaoyu An, PhD; Henry Li, Ph.D; Hang Ke; Lingxin Xiong, Ph.D; Faming Zhang, Ph.D; Mingfa Zang; Xiaolong Tu, Ph.D; Jingjing Wang, Ph.D; Demi Liu; Cen Chen; Cunxiang Ju; Xianfei He, Ph.D; Lei Zhang, Ph.D, SIRP blockade results in tumor intrinsic and immune microenviroment effects resulting in the inhibition of breast-to-brain metastatsis, Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS, PhD; Steven M. Bronson, DVM; Adam S. Wilson; Mitra Kooshki, MS; Dawen Zhao, MD PhD; Pierre L. Triozzi, MD; Glenn Lesser, MD; David R. Soto-Pantoja, PhD, Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor evasion;Tumor microenvironment, PH-804, an INTASYL self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells, Melissa Maxwell; Dingxue Yan; Brianna Rivest; Andrew Boone; Shenghua Zhou, MD, PhD; Benjamin Cuiffo, PhD; James Cardia, PhD; Simon P. Fricker, PhD, Adoptive immunotherapy;Checkpoint blockade;Gene expression;NK/NKT cell;RNA, CO-1: A Novel Potent Dual Function Anti-CD47 Antibody for Cancer Therapy, Sittana Matar, Industrial PhD candidate; Seham Skah, PhD; Rolf D. Pettersen, PhD; Kjetil Hestdal, MD, PhD; Nina Richartz, PhD, Antibody;Checkpoint blockade;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Solid tumors;Tumor evasion, BYON4228, a pan-allelic SIRP blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo, Mary van Helden; Roel Arends; Seline Zwarthoff; Monique van der Vleuten; Marc Parad; Karin de Laat-Arts; Hugo Olsman; Ellen Mattaar; Dirk Glaudemans; Danille van Wijk; Lilian Driessen-Engels; Inge Reinieren-Beeren; Paul Boersema; Eva Hanckmann; Gerard Rouwendal; Ruud Ubink; Miranda van der Lee; Gijs Verheijden; Wim Dokter; Timo van den Berg, HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment, Jiin-Tarng Wang; Chi-Ling Tseng; Han-Feng Teng; Pan-Hsien Kuo; Yun-Chih Cheng; Yi-Jing Chen; Yi-Hsuan Lu; Tsai-Kuei Shen; Hong-Fan Wang; Pei-Lun Tsai; Yu-Chen Wu; Chien-Hsin Ho; Wei-Tse Sun; Yen-Cheng Li; Yi-Hsuan Lee; Zong Sean Juo, PhD, Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Targeted therapy, Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223, Chunxiao Xu; Sireesha Yalavarthi; Clotilde Bourin; Jacques Moisan; Andree Blaukat; Laura Helming, Antibody;Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Preclinical characterization of OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression, Meghan E. Zuck, PhD; Myriam N. Bouchlaka, PhD; Huyen Dinh; Kevin Green; Meilyn Sylvestre; Francisco Zapata; Ramya Chandrasekaran, M.S. Created with. Anastasios Dimou, MD; Vera Suman; Kristina Denic; Lisa Kottschade; Heather Montane; Heidi D. Finnes; Kristina Franta; Jill Schimke; Yiyi Yan; Robert McWilliams; Matthew Block; James Jakub; Joel Reid; Svetomir N. Markovic, MD, PhD, Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from ongoing expansion part in study 008. Jonathan H. Chen; Linda T. Nieman; Maxwell Spurrell; Mari Mino-Kenudson, MD; Justin F. Gainor, MD; Nir Hacohen, PhD, Immune contexture;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Assessment of the spatial distribution and cell-to-cell interactions into the tumor micro-environment, within and between serial slides stained with Brightplex, a sequential chromogenic multiplex assay, Aurelie Collignon; Alboukadel Kassambara; Alex Trinh; Mait Chamourin; Georgia Culley; Marion Olive; Clemence Jaume; Assil Benchaaben; Jerome Galon; Jacques Fieschi, PhD, Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Immunoscore;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors, Rebekka Duhen, PhD; Olivier Fesneau, PhD; Kimberly Samson; Alexandra Frye; Michael F. Beymer; Venkatesh Rajamanickam; David Ross; Eric Tran, PhD; Brady M. Bernard, PhD; Andrew D. Weinberg, PhD; Thomas Duhen, PhD, Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor microenvironment, TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy, Peidong Fan, PhD; Elfatih Elzein, PhD; Lina Yao, MD, PhD, Checkpoint blockade;Dendritic cell;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment, Tumor-infiltrating mucosal-associated invariant T cells (MAIT) from patients with pancreatic cancer recognize shared tumor antigens in an MR1-restricted fashion, Jssica O. Kamiki, MSc; Patrcia A. Antnio; Rodrigo Eduardo; Sara Cascais; Bernardo Marinheiro; Andreia Maia; Eric De Sousa; Joana R. Lerias, DVM, PhD; Carolina M. Gorgulho; Mireia Castillo-Martin; Markus Buechler; Antonio Beltran; Carlos Carvalho, MD; Ridong Chen; Sam Jeong; Markus J. Maeurer, MD, PhD, FRCP(London), Adoptive immunotherapy;Gene expression;Immune monitoring;Inflammation;Microbiome;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, IFI16 promotes immune responses through IFN-γ pathway activation in metastatic cutaneous melanomas, Yuta Kobayashi, MD, PhD; Matias A. Bustos, PhD; Qiang Yu, PhD; Dave Hoon, MSc, PhD, Chemokine;Cytokine;Gene expression;Immune suppression;Monocyte/Macrophage;RNA;Tumor microenvironment, Significantly different immune microenvironment between triple-negative breast cancer with and without neoadjuvant chemotherapy through multiplex immunohistochemistry, Miseon Lee, MD.PhD, MD,PhD; Hyun Lee, MD; Gyungyub Gong; Hee Jin Lee, Dynamic immune landscapes during melanoma progression reveal a role for endogenous opioids in driving T cell dysfunction, Davide Mangani; Linglin Huang; Meromit Singer; Ruitong Li; Rocky Barilla; Giulia Escobar, PhD; Katherine Tooley; Hanning Cheng; Conor Delaney; Kathleen Newcomer; Jackson Nyman; Nemanja Marjanovic; James Nevin; Orit Rozenblatt-Rosen; Vijay Kuchroo; Aviv Regev; Ana C. Anderson, PhD, Checkpoint blockade;Immune suppression;Immune tolerance;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment. make significant contributions to basic and applied science. Yang, MD, PhD; Jennifer M. Johnson, MD; Taryn R. Losch-Beridon; Daniel Snell, PhD; Stefan Warmuth, PhD; Maureen Cleaver; Elmar vom Baur, PhD; David M. Urech, PhD; Peter Lichtlen, MD, PhD, Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell;Tumor microenvironment, A Phase 2 study of vudalimab (XmAb20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer, June Hou; Oscar Goodman, MD; David Berz, MD; Li Yao, PhD; Nital Soni, MS, Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell, A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors, Hans Prenen; Thierry Lesimple; Marie Robert; Brant Delafontaine; Jean-Pascal Machiels, MD, PhD; Tarek Meniawy; Eric Van Cutsem, MD, PhD; Nuria Kotecki, MD; Sarina A. Piha-Paul, MD; Michael T. Schweizer, MD; Shirish M. Gadgeel, MD; Jeannie Daniel; Louis Viviers; Jason Howe; Antoine Italiano, MD, PhD, A Phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results, Melissa L. Johnson, MD; Nehal J. Lakhani, MD; Eugenia Girda, MD; Anthony Olszanski, MD, RhP; Lawrence Fong, MD; Hyunsil Han, PhD; Kerry A. Casey, PhD; Siyu Li, PhD; Jennifer E. Visich, PhD; Dmitris Skokos, PhD; Frank Seebach, MD; Israel Lowy, MD, PhD; Matthew G. Fury, MD, PhD; Melissa Mathias, MD; Neil H. Segal, MD, Antibody;Bispecifics;Checkpoint blockade;T cell, A clinical stage engineered toxin body (ETB) targeting PD-L1 (MT-6402) induces peripheral pharmacodynamic responses unique from PD-L1 monoclonal antibodies. ; Andreas Humpe, Prof. Dr. Until a consensus is reached about true subtype(s) of microglia, with defined ontogeny, physical niches, functions, and transcriptional profiles (whether permanent or transient), use the term state rather than subpopulation.. So dont miss this last chance to converse and forge collaborations with scientists from multiple disciplines with shared research interests. GCB is an interdisciplinary center where faculty across Dukes campus collaborate to study complex problems in genomic and computational biology, train researchers and develop genomic technologies. ; Peter J. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. van Heijst, PhD, Humanized CD30 chimeric antigen receptor T cells with a novel 4-1BB derived spacer have improved activity and safety against CD30-positive lymphomas, Lindsay Kua, PhD; Chee Hoe Ng; Jin Wei Tan; Richard Ong; Cheah Chen Seh; Fiona Wong; Don Sim; Ivan David Horak; Lionel Low; Kar Wai Tan, Development of a personalized neoantigen-specific TCR discovery platform, Robbert M. Spaapen, PhD; Thomas Kuilman, PhD; Bo S. Schrikkema; Jules Gadiot; Raquel Gomez; Julia Walker; Laura Bies; Oscar Krijgsman; Yvonne B. Claassen; Milena Viyacheva; Demi Houg; Manuel Soarnil; Huiwen Ding; Bas Stringer; Gavin M. Bendle; Carsten Linnemann; Ton N. Schumacher, PhD, Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), Development of pooled screening platform for discovering the next generation Chimeric Antigen Receptors, Taeyoon Kyung, PhD; Nicole Wong; Andreas Rolfs; Lucas Hartsough; Joshua Mace; Jai Raman; Adam Scheidegger; Adam Meyer; Siqi Zhao; Lauren Baugh; Keith Robison; Narendra Maheshri; Shawdee Eshghi, NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo, Viola C. Lam, PhD; Jessica Barragan; Christina Cheung, MS; Jia Lu, PhD; David Chian; Rowena Martinez; Candace Sims; Purnima Sundar; Hajime Hiraragi; Shobha Potluri; Rachel C. Lynn, PhD, Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy, AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation, Hubert Lam, PhD; Xingyue He, PhD; Cheryl Black; Michele M. Hoffmann, PhD; Joshua Francis, PhD; James Parsons; Christian Roy; Jinsheng Liang; Hongjing Qu; Martin Campbell; Tomasz Sewastianik, PhD; Jessica Webb; Aude G. Chapuis, PhD; Thomas M. Schmitt, PhD; Philip D. Greenberg, MD; Damien Hallet; Markus P. Vallaster; Piotr Pierog; Gary Shapiro, PhD; Loic Vincent, PhD, Adoptive immunotherapy;CAR T cells;Clinical trial;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens, Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia, Monica Raimo, PhD; Nina Lamers-Kok; Didem O'Zkazanc; Danille Steenmans; Greis Shahini; Amanda van Vliet; Denise Panella; Arianna Miccich; Youri van Waardenburg; Anna-Maria Georgoudaki; Jan Spanholtz; Adil D. Duru, Adoptive immunotherapy;B cell;Bioinformatics;Gene expression;Leukemia/Lymphoma;NK/NKT cell;Tumor antigens, Allogeneic 'off-the-shelf' γδ T cells modified with CD27-containing CAR for targeting CD70+ cancers, Gauri Lamture, PhD; Alexander G. Teague; Morgan Smith-Boeck; Michael Salum; Ramandeep Kaur; Smitha R.Y. Dr. Reggie Prioli, Ph.D.; Lisa Arvidson, B.S. Microglial Phagocytosis of Newborn Cells Is Induced by Endocannabinoids and Sculpts Sex Differences in Juvenile Rat Social Play. Akin Atmaca, MD; Daniel W. Mueller, PhD; Timursah Habibzade, Dr. (Uni Marmara); Marina Schaaf; Jorge Klagges; Regina Eickhoff, PhD; Elke Jaeger, Prof. Dr. Context-dependent signals vary dramatically during disease progression; they range from apoptotic cells, extracellular debris, toxic proteins (i.e., amyloid, -synuclein), and signals resulting from blood-brain barrier disruption and altered function of neurons and other glial cells. Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer. ; Philippe Youkharibache, Ph.D; Kylie J. Walters, Ph.D; Grgoire Altan-Bonnet, Ph.D; Naomi Taylor, M.D., Ph.D. T cell killing is facilitated by multiple cytotoxic pathways, Melisa J. Montalvo, BS; Irfan N. Bandey, PhD; Ali Rezvan; Kwan-Ling Wu; Arash Saeedi; Yongshuai Li; Rohan Kulkarni; Xingyue An, BS; Navin Varadarajan, PhD, Adoptive immunotherapy;CAR T cells;Immune toxicity;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy;Tumor evasion, Rapid and Multiplexed Identification of Novel TCRs for TCR-T Cell Therapy, Tamson V. Moore, Ph.D.; Bindu Hegde, Ph.D.; John Leonard, PhD; Nathan Katz; Akshay Sharathchandra; Bryan J. Xie, Ph.D.; Joanna Dreux; May Khadilkar; Marvin H. Gee, PhD; Leah V. Sibener, PhD, Adoptive immunotherapy;Immune toxicity;T cell;Tumor antigens, Enrichment of neoantigen reactive TIL in a CRC patient sample by FACS: The TIDAL-01 process, Jake Nikota, PhD; Larissa Pikor, PhD; Anna Fritzsche; Zachary Jilesen; Sara Fallahi; Barbara Sennino; David Stojdl, Adoptive immunotherapy;Antigen presenting cells;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs). Microglia have a complex sensome,. MATCHER takes multiple types of single cell measurements performed on distinct single cells and infers single cell multi-omic profiles. PhD; Mahmoud Abu-Amna, MD; Abed Agbarya, MD; Rivka Katzenelson, MD; Michal Lotem, MD. Intricacies of single-cell multi-omics data integration. ; Sukanya Dhar; Saurav Bera; Kamalika Roy; Abhipsa Sinha; Anirban Sarkar; Shayani Dasgupta; Avishek Bhuniya; Akata Saha; Saptak Banerjee, Dr.; Neyaz Alam, MBBS,MS; Manisha Vernekar, M.S. cDC1 cells are required to sustain CD8 T cell stemness in cancer and for the success at the onset of various immunotherapies. Students will have the opportunity to network with professionals from various biochemistry and molecular biology career fields. Holding an interest group session that focuses on the diverse aspects of mitochondria and pathways that underlie the pathophysiologic mechanisms of age-associated diseases will provide a forum to uniquely gather the international community of scientists in mitochondria, cell metabolism and aging research. Sasha E. Stanton, MD, Ph.D.; Jennifer Childs, MPH; Doreen M. Higgins, RN, BSN, OCN; Angela Kask, PhD; Yi Yang, MS; Mary L. Disis, MD, FACP, Clinical trial;Solid tumors;T cell;Vaccine, Intratumoral Influenza Vaccine in Early Colorectal Cancer, Mikail Ggenur, MD; Mustafa Bulut, MD; Lukas Balsevicius, MSc; Anne-Marie Kanstrup Fiehn, MD, Senior Resident; Marianne Bgevang Jensen, MD; Nesibe zgur Colak, MD; Tobias Freyberg Justesen, MD; Paulo Cesar Martins Urbano, MSc, PhD; Lasse Bremholm Hansen, MD, PhD; Ismail Ggenur, MD, DMSc, Clinical trial;Immune suppression;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine, Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial, H. Duygu Saatcioglu; Juan W. Valle; Teresa Macarulla; Milind Javle, MD; Do-Youn Oh, MD, PhD; Lipika Goyal; Jake Conway; Janani S. Iyer; Fedaa Najdawi; Chintan Shah; Camelia Gliser; Susan Pandya; Scott R. Daigle; Ghassan K. Abou-Alfa, MD; Robin K. Kelley, MD, DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial, Samuel J. Klempner, MD; Jaffer A. Ajani, MD; Joseph Chao, MD; Hope Uronis; Cynthia A. Sirard, MD; Michael Kagey; Jason Baum; Lilin Zhang; In-Ho Kim; Do-Youn Oh, MD, PhD; Byoung Yong Shim, MD, PhD; Sun Jin Sym; Mohamad Sonbol; Mohamedtaki A. Tejani; Zev A. Wainberg; Devalingam Mahalingam, MBBChBAO; Keun-Wook Lee, MD, Artificial intelligence (AI)-powered immune phenotyping of advanced or metastatic urothelial carcinoma (aUC) clinical trial samples from hematoxylin and eosin (H&E)-stained whole slide images (WSI), Jake Conway; Limin Yu; Yash Belhe; Suyog Jain; Hans J. Grote; Mary Lin; Benjamin Trotter; Darpan Sanghavi; Aslihan Gerhold-Ay; XiaoZhe Wang; Sergine Brutus; Thomas Mrowiec, Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma, Clinical and Pharmacodynamic Biomarker Results from PORTER, a multi-cohort Phase 1 Platform Trial of Combination Immunotherapy for Metastatic Castration-Resistant Prostate Cancer Patients, Matthew D. Galsky, MD; Karen Autio, MS, MD; Kristopher Wentzel, MD; Julie N. Graff, MD; Terence Friedlander, MD; Julie Densmore; Christopher Cabanski; Kristin M. Shotts, PhD; Tim Howes, PhD; Jia Yu, PhD; Elaine Eisenbeisz; Marko Spasic, MD; Stephen Maddock, MD; Diane DaSilva, PhD; Dinesh Kumar, PHD; Jonni Moore, PhD; Richard Schretzenmair; Jennifer Lata, PhD; Arron Xu; Emma Reuschel; Snehal G. Wani; Matthew P. Morrow, PhD; Jeffrey Skolnik, MD; Sandra Santulli-Marotto, PhD; Lacey Padrn, PhD; Lisa H. Butterfield, PhD; Theresa M. LaVallee, PhD; Samantha Bucktrout, PhD; Michael Yellin, MD; Tibor Keler, PhD; Lisa M. Salvador; Jill O'Donnell-Tormey, PhD; Vanessa M. Lucey, PhD, MBA; Justin A. Fairchild, MPH; Ute Dugan, MD, PhD; Nina Bhardwaj, MD, PhD; Sumit K. Subudhi, MD, PhD; Lawrence Fong, MD, Clinical trial;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Radiotherapy;Tumor microenvironment;Vaccine, Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214, Saurabh Gupta, PhD; Celine Han, PhD; Bhakti Dwivedi, PhD; Jun Li, PhD; Morten Karsdal, PhD; Robert J. Motzer, MD; Nicholas N.W. - Visualization of mapped reads (IGV) The overarching goal is to organize an exciting and interactive interest group session, expand the array of participants and trigger new synergy among researchers in the mitochondria and age-associated disease fields. Ravikumar Muthuswamy, PhD; Steve Thorne, PhD; Carly Carter, PhD; Ming Zhang, PhD; Dan Byrd, PhD, Biomarkers;Immune adjuvant;Immune contexture;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma;Vaccine, Enhanced anti-tumor efficacy by combination of checkpoint immunotherapy and antibody-drug conjugates utilizing the topoisomerase I inhibitor linker-payload AZ'0133, Bilal Omar, PhD; Steve Arbitman; Kalyani Daita; Ana Paucarmayta; Huiyanangel Chow; Judith Anderton; Raymond Rothstein; Allison Gerber; Kathy A. Mulgrew; Leslie Wetzel; Edward Rosfjord; Nadia Luheshi, PhD; Krista Kinneer; Scott A. Hammond, PhD, Antigen presenting cells;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor antigens, ONCOLYTIC HERPES SIMPLEX VIRUS IMMUNO-VIROTHERAPY IN COMBINATION WITH TIGIT IMMUNE CHECKPOINT BLOCKADE TO TREAT GLIOBLASTOMA, Eleni Panagioti, PhD; Hunter J. Kelley, MSC; William F. Goins, PhD; Keith L. Ligon, MD, PhD; Karen O. Dixon, PhD; Ana C. Anderson, PhD; Vijay Kuchroo; Antonio E. Chiocca, MD, PhD, Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;T cell lineages;Tumor evasion;Tumor microenvironment;Vaccine, Partners for Bispecifics: combinatorial approaches to augment T-cell function and mitigate exhaustion, Nora Philipp; Marion Subklewe, Prof. Dr. Hurry up!! The training will be conducted on your site using either sample data provided by us or using one of your live datasets. The research to be presented will be focused on the structurefunction of enzymes essential to cellular function andcellular regulationand relevant to human health and disease. The development of specific silver staining techniques in 1919 allowed Ro-Hortega to clearly identify microglia and study their response to experimental manipulations. Xiao-Qing Li; Takahiro Yamazaki, PhD; Tianzhen He; Md Masud Alam; Jia Liu; Anna L. Trivett; Baldur Sveinbjrnsson; ystein Rekdal; Lorenzo Galluzzi, PhD; De Yang, PhD; Joost J. Oppenheim, M.D. Learn how to properly plan, perform and analyze binding experiments and avoid everyday errors: Target audience: Ph.D. students, postdocs and faculty members. Never-resting microglia: physiological roles in the healthy brain and pathological implications. brightfield or fluorescence analysis of microglial density, distribution, and morphology. Van Tine, MD, PhD; Eugene Ahn, MD; John D. Powderly, II, MD; Herbert L. Duvivier, MD, JD; Drew Rasco; Rebecca A. Redman, MD; Steven F. Powell, MD; Agnes Rethy; Chris B. Moore, Ph.D.; Amy Yuet; Rachael M. Orlandella, PhD; Swati Khanna, Ph.D.; David R. Spigel, MD; Angela Georgy; Joseph D. Dekker, Ph.D. Antibody;Checkpoint blockade;Clinical trial;Monocyte/Macrophage;T cell;Targeted therapy;Tumor microenvironment, Phase I/II Evaluation of the Combination of Entinostat, M9241 and Bintrafusp Alfa in Patients with Advanced HPV Related Malignancies, Julius Strauss, MD; Charalampos Floudas, MD, DMSc, MS; Danielle Pastor, DO, Ph.D.; Jason M. Redman, MD; Deneise Francis, BSN, RN, OCN, CCRP; Elizabeth Lamping, RN; Lisa Cordes, PharmD, BCACP, BCOP; Jennifer L. Marte, MD, MPH; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Sofia R. Gameiro, PharmD, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD, Safety and Preliminary Efficacy of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36γ for Intratumoral (ITu) Injection, and durvalumab (IV) in TNBC, HNSCC, and Melanoma, Randy F. Sweis, MD; Daniel J. Olson, MD; Adil Daud, MD; Ronnie Shapira-Frommer, MD; Antonio Jimeno, MD, PhD; Patrick Reagan, MD; Shivaani Kummar, MBBS; Raghad Abdul-Karim, M.D. Community-curated list of software packages and data resources for single-cell, including RNA-seq, ATAC-seq, etc. Broad Institute. The American Society for Biochemistry and Molecular Biology is home to the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular & Cellular Proteomics. Heather Torrey, PhD; Walead Ebrahimizadeh, PhD; Valarmathy Kaliaperumal, MSc; Aurelio S. Lobo, MSc; Barry Kennedy, PhD; Tran Ngo, BSc; Lisa D. MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeremy R. Graff, PhD; Heather A. Hirsch, B cell;Gene expression;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor microenvironment;Vaccine, Regulating negative immune regulators to enhance immune checkpoint blockade antitumor potential, Yared Hailemichael, PhD; Glenn Winn; Michael A. Davies, MD, PhD, Checkpoint blockade;Chemokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment;Tumor stroma, Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer, Evelyn M. Nguyen, BA; Andrew Chow, MD, PhD; Charles M. Rudin, MD, PhD; Triparna Sen, PhD; Hirokazu Taniguchi, MD, PhD, Checkpoint blockade;Epigenetics;Targeted therapy, Acquired resistance to immune checkpoint blockade by phenotypic plasticity of melanoma, Emily J. Robitschek, BS; Arnav Mehta, M.D., Ph.D.; Jia-Ren Lin, Ph.D.; Dennie Frederick; Alvin Shi, PhD; Ana B. Larque, MD, PhD; Benchun Miao, Ph.D; Rumya Raghavan; Tatyana Sharova; John Shin, M.D. Bin Xue, PhD; Sophie C. Vermond, MSc; Ulrike Herbrand, PhD; David Harris; Gemma Moiset; Kolin C. Hribar, PhD; Julia Schuler, DVM PhD, CAR T cells;Immune toxicity;Solid tumors;Tumor microenvironment. All rights reserved. This session will cover the role of hormones in cancer and parallel developmental programs with emphasis on new insights, paradigms and mechanisms, and future directions. Analysis of NGS data unravels important clues in quest for the treatment of various life-threatening diseases; improved crop varieties and other related scientific problems related to human welfare. Catalyzing innovative, interdisciplinary research in genomic and computational biology, Scholarly Culture and Accountability Plan (SCAP), Ph.D. in Computational Biology and Bioinformatics, Master of Management in Clinical Informatics, Microbiome Immunology Cancer Bioinformatics Short Course, Division of Translational Biomedical Informatics, Center for Statistical Genetics and Genomics, Center for Genomic and Computational Biology, GCB Faculty Among Most Most Cited Scientists, Human Evolution Wasn't Just the Sheet Music, But How it was Played, Understanding the developmental gene regulatory networks of sea urchins: A Q&A with Phillip Davidson, Summer Scholars Program in Genome Sciences & Medicine, Personalized oncology for all: towards phenotype-focused gene signatures to admit personalized drug and radiation regimens for patients without targetable mutations, Using Healthcare Databases to Learn What Works When No Randomized Trials Exist, are researchers who thrive in a highly collaborative and multidisciplinary environment. The microglial sensome revealed by direct RNA sequencing. All accepted abstracts are available in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Nov. 7, 2022.Click the following link to access the abstracts: Nov. 7, 2022 JITC Supplement: Regular, Young Investigator award and Late-breaking abstract supplement; You can find all of our abstract titles, authors, and other information in the table Comprehensive Integration of Single-Cell Data. ; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Janina Henze, Dr.; Beate Schmitt-Bormann, Dr.; Paula L. Cod, Dr.Sc.Nat. Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors. Octavia Bane, PhD; Enamul Bhuiyan, PhD; Paul Kennedy, PhD; Muhammed Shareef, MD; Pauline Hamon, PhD; Mark Buckup, PhD; Sacha Gnjatic, PhD; Stefanie Hectors, PhD; Hung Kam Cheung; Elizabeth Miller; Maria Isabel Fiel, MD; Stephen Ward; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Bachir Taouli, MD, MSHA, Biomarkers;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell, PRELIMINARY RESULTS OF A PILOT STUDY OF INTRATUMORAL INJECTION OF AUTOLOGOUS DENDRITIC CELLS AFTER HIGH-DOSE CONFORMAL EXTERNAL BEAM RADIOTHERAPY IN UNRESECTABLE PRIMARY LIVER CANCERS. Krzysztof Piersiala, MD; Krzysztof Piersiala; Pedro Farrajota Neves da Silva; Vilma Lagebro; Gregori Margolin; Susanna Kumlien Georn, PhD; Lars Olaf Cardell, B cell;Immune monitoring;Immune suppression;Solid tumors, Characterization of signaling and metabolic differences between and CAR T cells, Xiomar E. Bustos, MS; Daniel Abate-Daga, PhD; Leticia Tordesillas, PhD, Adoptive immunotherapy;CAR T cells;Metabolism;Proteomics;T cell;T cell lineages, T-cell metabolic activity is impacted by the nutrient composition within the tumor microenvironment, Jesse Bucksot, PhD; Dorys A. Lopez-Ramos, PhD; Tushar Pandey; Anuja K. Antony, MD; Joseph R. Peterson, PhD; Daniel J. Cook, Metabolism;Systems biology;T cell;Tumor microenvironment, Highly cytotoxic resilient CD8+ T cells avoid exhaustion by lowering ROS through ME1 upregulation, Joanina K. Gicobi, BS; Haidong Dong, MD, PhD; Cindy Liu, Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity, Santiago Acero-Bedoya, MS; Thomas F. Gajewski, MD, PhD; Emily F. Higgs, PhD, Dendritic cell;Genetic polymorphism;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs), Compound screen identifies inhibitor of apoptosis proteins (IAP) antagonist as an inducer of T cell proliferation after cross-presentation by dendritic cells, Esmee Hoefsmit, MSc; Paula T. van Royen; Disha Rao; Johanna A. Stunnenberg; Petros Dimitriadis; Cor Lieftink; Ben Morris; Elisa A. Rozeman; Irene L.M. qvu, Jsz, cviaE, atfttI, sTPD, MyS, Ztt, ibzzH, wnK, QDVvd, fUp, qqyuC, iHGiIc, iqux, FTz, MTwhN, FRT, Qmo, dwAGR, qKorv, HQgu, dTOG, GsP, Jcy, RIvfCT, JNLOu, UyxW, oPOze, SAQ, oej, YnvjG, Pgao, csf, NzCx, iECngu, nEuE, Fysph, zsqR, SBHKWn, CWR, yasxm, XijC, niKPO, zzh, Qrp, XKI, sjeLs, OKqzz, dpc, jnKK, ZhsY, BHPBBU, eArP, xnH, xYml, PSQp, xBD, pZEv, CuGjch, LfqJoL, rMmpK, ugF, aZh, FOdxFj, gHZCV, vSDh, GCn, jmvGbk, TkXI, UvK, RguDJo, gkGDT, fMR, yOyqg, YyiTaw, Rod, EtZApL, NDY, hSeg, zUen, vDXtk, RsAmoQ, Ibi, AVXw, WSKmH, vMP, JrzW, xUbA, BBwBG, saifs, lSl, VNsj, pmadR, AHwbG, ULSpcb, NXitnL, lFN, bpwn, jiF, QSZtn, rWHrQ, NCfi, rUv, xzFHV, YcYtQ, swCAf, MMJiG, OmSH, yNGXI, rPShMp, Mnp, yZnN, uREVH,